Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study

BJ Solomon; B Besse; TM Bauer; E Felip; RA Soo; DR Camidge; R Chiari; A Bearz; CC Lin; SM Gadgeel; GJ Riely; EH Tan; T Seto; LP James; JS Clancy; A Abbattista; JF Martini; J Chen; G Peltz; H Thurm; SH Ignatius Ou; AT Shaw

Journal article

Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study

BJ Solomon, B Besse, TM Bauer, E Felip, RA Soo, DR Camidge, R Chiari, A Bearz, CC Lin, SM Gadgeel, GJ Riely, EH Tan, T Seto, LP James, JS Clancy, A Abbattista, JF Martini, J Chen, G Peltz, H Thurm Show all

Lancet Oncology | ELSEVIER SCIENCE INC | Published : 2018

DOI: 10.1016/S1470-2045(18)30649-1

Abstract

Background: Lorlatinib is a potent, brain-penetrant, third-generation inhibitor of ALK and ROS1 tyrosine kinases with broad coverage of ALK mutations. In a phase 1 study, activity was seen in patients with ALK-positive non-small-cell lung cancer, most of whom had CNS metastases and progression after ALK-directed therapy. We aimed to analyse the overall and intracranial antitumour activity of lorlatinib in patients with ALK-positive, advanced non-small-cell lung cancer. Methods: In this phase 2 study, patients with histologically or cytologically ALK-positive or ROS1-positive, advanced, non-small-cell lung cancer, with or without CNS metastases, with an Eastern Cooperative Oncology Group perf..

View full abstract